Here’s Why These Cannabis ETFs Aren’t Very Good

You’re reading a copy of this week’s edition of the New Cannabis Ventures weekly newsletter, which we have been publishing since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve as well as links to the week’s most important news.

Friends,

We have been critical of the cannabis ETFs for a while, and they are all down hard in 2023:

Today, we want to take a close look at some cannabis ETFs and to explain again why investors should not invest in ETFs if they want to invest in cannabis.

AdvisorShares Pure US Cannabis ETF (MSOS), at just over $300 million,  continues to have the same challenge that we have highlighted: It is poorly diversified, with over 47% in two names, GTI and Curaleaf. The top 6 holdings approximate 87%, and this is out of line with their economic contribution to the industry and their market caps. The ETF has no stated index. We remain concerned that potential redemptions could fuel selling of the six largest holdings, especially the largest two.

In the past, I suggested that Amplify Seymour Cannabis ETF (CNBS), only $24 million, might be a better ETF than MSOS, and it has been in 2023, but it’s not doing a good job on stock selection. I like that it’s not as concentrated as MSOS, but its top two holdings are Curaleaf and Tilray. We don’t believe that either of these stocks should be owned by investors right now.

ETFMG Alternative Harvest ETF (MJ), at about $200 million, is down the most, and the security selection there is challenging. Over 12% of the ETF is in two large Canadian LPs that worry us, Canopy Growth and Tilray, and about 47% is in its own fund, ETFMG Alternative Harvest ETF (MJUS). This fund is mainly held by MJ, and it has about 26% in Curaleaf and GTI.

This has been a tough year for cannabis investors, as the New Cannabis Ventures Global Cannabis Stock Index set a new all-time low this past week and is down 24.4% year-to-date. We think that the market is just for long-term investors right now, and these ETFs aren’t the right way to invest in the cannabis market. Investors can save on the fees that are embedded in the ETFs and build more diversified portfolios, or they can load up on better stocks if they want to do so.

Like this newsletter? Sign up, and you will receive a free copy by email each Sunday morning. Each week, we share the top stories and write an original perspective as well.

New Cannabis Ventures publishes curated articles as well as exclusive news. Here is some of the most interesting business content from this week:

Exclusives

To get real-time updates download our free mobile app for Android or Apple devices, like our Facebook page, or follow Alan on Twitter. Share and discover industry news with like-minded people on the largest cannabis investor and entrepreneur group on LinkedIn.

Use the suite of professionally managed NCV Cannabis Stock Indices to monitor the performance of publicly-traded cannabis companies within the day or over longer time-frames. In addition to the comprehensive Global Cannabis Stock Index, we offer the Canadian Cannabis LP Index, the American Cannabis Operator Index and the Ancillary Cannabis Index.

View the Public Cannabis Company Revenue & Income Tracker, which ranks the top revenue producing cannabis stocks.

Stay on top of some of the most important communications from public companies by viewing upcoming cannabis investor earnings conference calls.

Discover upcoming new listings with the curated Cannabis Stock IPOs and New Issues Tracker.

Sincerely,

Alan & Joel

Based in Houston, Alan leverages his experience as founder of online community 420 Investor, the first and still largest due diligence platform focused on the publicly-traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. At New Cannabis Ventures, he is responsible for content development and strategic alliances. Before shifting his focus to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst following over two decades in research and portfolio management. A prolific writer, with over 650 articles published since 2007 at Seeking Alpha, where he has 70,000 followers, Alan is a frequent speaker at industry conferences and a frequent source to the media, including the NY Times, the Wall Street Journal, Fox Business, and Bloomberg TV. Contact Alan: Twitter | Facebook | LinkedIn | Email